BG
CCCC icon

Bellevue Group’s C4 Therapeutics CCCC Stock Holding History

Bellevue Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-57,600
Closed -$266K – 168
2024
Q2 		$266K Hold
57,600
– – ﹤0.01% 142
2024
Q1 		$471K Sell
57,600
-4,400
-7% -$34.1K 0.01% 132
2023
Q4 		$350K Buy
+62,000
New +$141K 0.01% 144
2022
Q2 		– Sell
-54,500
Closed -$1.32M – 176
2022
Q1 		$1.32M Buy
54,500
+7,300
+15% +$177K 0.02% 141
2021
Q4 		$1.52M Hold
47,200
– – 0.02% 151
2021
Q3 		$2.11M Buy
47,200
+16,200
+52% +$694K 0.02% 146
2021
Q2 		$1.17M Buy
+31,000
New +$1.11M 0.01% 150

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group's CCCC Position: Q3 2024 in Review

Bellevue Group sold out of C4 Therapeutics (CCCC) in Q3 2024, closing a stake of 57,600 shares — an estimated $266K sold.

Bellevue Group first reported a position in CCCC in Q2 2021 and held it in 7 quarters. The position peaked at $2.11M in Q3 2021. 118 funds tracked by Wall St. Rank hold CCCC as of Q3 2024.

  • Bellevue Group reported no remaining C4 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bellevue Group sold 57,600 C4 Therapeutics shares in Q3 2024, an estimated $266K.
  • Bellevue Group first reported a position in C4 Therapeutics in Q2 2021 and held it in 7 quarters.
  • Bellevue Group's C4 Therapeutics position peaked at $2.11M in Q3 2021.
  • 118 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2024.

Based on Bellevue Group's 13F filing for Q3 2024, filed 14 Nov 2024.